公司简介/CO. INTRODUCTION

——


上海谷森医药有限公司简介

 

上海谷森医药有限公司以高端制剂,特别是以新一代高效吸入剂-吸入软雾剂技术产品为核心,以欧美国际化开发和产业化发展为目标,联合北大、复旦、中科院上海药物所和沈阳药科大学等研发平台资源,创建和打造本领域国内一流、国际领先的研发团队和研发/产业化基地,以及“产学研”生态链。同时为国内外高端制剂/吸入剂行业提供技术产品解决方案,为广大病患提供高质量负担得起的药品,把我国高端制剂提升到世界领先水平。

 

 

v 公司在上海、南昌和宁波设有研发中心。有三个吸入软雾制剂品种入选国家十三.五“重大新药创制”科技重大专项。吸入软雾剂研发和产业化走在国内外同行的前列。公司已开发了丰富的产品线,有5个在研的吸入软雾剂首仿药,其中两个在中试阶段。而且许多后备产品:有10个吸入软雾剂为505(b)2 新药(国内2类新药),这些产品有约200亿美元的全球市场。公司开发和申请了一系列吸入软雾剂专利,占领了该领域的制高点。为国内唯一获得吸入软雾剂国家“重大专项”的企业。


 Our Purpose

 We aim for better life of the worldwide patients by providing medicines through integrating quality, reliability, consistency and innovation.

 Anovent Pharmaceutical was established in 2014 as a leading pharmaceutical company that develops a new generation of high-quality, efficient, safe and affordable inhalation medicines (both generic and innovative pharmaceuticals) for people around the world. Our company has established an internationally known R&D team and industrial manufacturing base. We have three R&D centers located in Shanghai, Nanchang and Ningbo, and a pilot and industrial manufacturing base in Nanchang. A number of inhalation medicines have been awarded as "Major Special Project" into the China's National Thirteenth-Five Year science and technology. The company has developed a rich product line consisting of several 505(b) 2 and innovative drugs which have a global market of about US$20 billion. The development and commercialization of these products are in the forefront around world. We have developed and filed a series of patents and it is the only enterprise in the country that has obtained "Major Special Project" for manufacturing and developing highly efficient and safe inhalation products.